• KOL
    • Type 1 Diabetes
    • David B Dunger
    • David B Dunger: Influence Statistics

      David B Dunger

      David B Dunger

      Show email address

      Institute of Metabolic Science, University of Cambridge, Cambridge, UK | Department of Paediatrics, Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K. | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      David B Dunger:Expert Impact

      Concepts for whichDavid B Dungerhas direct influence:Type 1 diabetes,1 diabetes,Type 1,Insulin sensitivity,Growth hormone,Growth factor,Insulin resistance,Diabetes mellitus.

      David B Dunger:KOL impact

      Concepts related to the work of other authors for whichfor which David B Dunger has influence:Type 1 diabetes,Insulin resistance,Birth weight,Growth hormone,Gestational age,Diabetic ketoacidosis,Polycystic ovary syndrome.

      KOL Resume for David B Dunger

      Year
      2022

      Institute of Metabolic Science, University of Cambridge, Cambridge, UK

      Department of Paediatrics, Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K.

      2021

      Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK

      Department of Food Science and Technology, University of California, Davis, USA.

      2020

      Wellcome Trust–Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.

      Metabolic Research Laboratories, University of Cambridge, Box 289, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.

      Department of Paediatrics, University of Cambridge, Cambridge, United Kingdom

      2019

      Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK.

      Department of Paediatrics, University of Cambridge, Cambridge, U.K

      Metabolic Research Laboratories and MRC Metabolic Diseases Unit

      2018

      Department of Paediatrics, Addenbrooke’s Hospital, University of Cambridge, Hills Road, Box 116, CB2 0QQ, Cambridge, UK

      Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K.

      2017

      From the Department of Paediatrics (M.L.M., D.B.D.) and the Wellcome Trust–Medical Research Council Institute of Metabolic Science (D.B.D.), University of Cambridge, and the Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital (S.B., S.D.), Cambridge, the National Centre for Cardiovascular Prevention and Outcomes, University College London (S.T.C., J.D.), and the WellChild Laboratory, Evelina London Children’s Hospital, St. Thomas’ Hospital (R.N.D.), London, the Institute of Cellular Medicine (Diabetes), Faculty of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne (S.M.M.), and the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford (H.A.W.N.) — all in the United Kingdom

      Department of Paediatrics, University of Cambridge, Cambridge, UK Department of Medicine, UK

      Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, U.K, .

      2016

      Division of Paediatric Endocrinology, University Children's Hospital, Tübingen, Germany;, Endocrine Care, Pfizer Health AB, Sollentuna, Sweden;, Tanaka Growth Clinic, Tokyo, Japan;, Endocrine Care, Pfizer Inc., New York, NY, USA;, Department of Paediatrics, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK;, Center for Endocrinology, Diabetes and Metabolism, The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA, USA

      Department of Paediatrics, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK

      Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, U.K

      Sign-in to see all concepts, it's free!
      Sample of concepts for which David B Dunger is among the top experts in the world.
      Concept World rank
      earlyinsulin control #1
      igfi iapp #1
      trimester lipids #1
      boys adiponectin levels #1
      natural diabetes insipidus #1
      infancy length #1
      skeleton androgens #1
      mpw 814 weeks #1
      hyperfiltration greater odds #1
      − storage temperature #1
      ee2 14 years #1
      day ratio acr #1
      value02 #1
      mmtt participants #1
      somatotropin remission #1
      1 year air #1
      storage degrees #1
      foetal h19 variants #1
      study rhigf #1
      onset bmi #1
      androgenaemia #1
      day sensor glucose #1
      rural–urban variations #1
      esrage levels subjects #1
      parental lipid levels #1
      insulin resistance gsinres #1
      synchronized approach #1
      verylowbirthweight infants hyperglycemia #1
      nonobese patients pco #1
      gfd bmi sds #1
      insulin dependent #1
      233 evaluable #1
      lipid metabolism pegvisomant #1
      precocious pubarche risk #1
      growth igf1 concentrations #1
      conventional csii time #1
      hm scfas #1
      hba1 microalbuminuria #1
      acr pua #1
      auccpep #1
      practice guideline diagnosis #1
      paternal association #1
      79±08 #1
      absorption patterns #1
      t1d body mass #1
      creatine cytokines #1
      cgms glucose control #1
      year ethinyloestradiol #1
      sexes stages #1
      Sign-in to see all concepts, it's free!

      Prominent publications by David B Dunger

      KOL-Index: 17742

      Diabetes insipidus is a well-recognized complication of Langerhans-cell histiocytosis (histiocytosis X), but its frequency and natural history are not well defined. Of 52 children with histiocytosis whom we studied, 12 (23 percent) had diabetes insipidus. Only two children had diabetes insipidus at presentation with histiocytosis, but the cumulative risk that it would develop during the first four years after the presentation and diagnosis of histiocytosis was found to be 42 percent. ...

      Known for Diabetes Insipidus | Posterior Pituitary | Cell Histiocytosis | Multisystem Disease | Cumulative Risk
      KOL-Index: 17508

      BACKGROUND: The achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older.

      METHODS: In this open-label, multicentre, multinational, single-period, parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four ...

      Known for Loop Insulin | 1 Diabetes | Difference 95 | Randomised Trial | Sensoraugmented Pump Therapy
      KOL-Index: 17149

      Aims/hypothesisType 2 diabetes risk is associated with low birth weight, rapid weight gain during childhood, and shorter stature and lower circulating IGF-I levels in adults. The largest variations in growth rates occur during the first postnatal years. We hypothesised that early postnatal variations in height and weight gain and IGF-I levels may be associated with risk markers for adult disease.MethodsWe measured the fasting insulin sensitivity (Homeostasis model) and insulin secretion ...

      Known for Insulin Sensitivity | Postnatal Growth | Normal Children | 8 Years | Size Birth
      KOL-Index: 16310

      OBJECTIVE: To compare blood glucose control and incidence of nocturnal hypoglycemia in adolescents with type 1 diabetes on multiple injection regimens managed with either an insulin analog combination or NPH insulin plus regular human insulin.

      RESEARCH DESIGN AND METHODS: In a randomized cross-over study, 28 adolescents with type 1 diabetes on multiple injection therapy received either insulin glargine prebedtime plus lispro preprandially (LIS/GLAR) or NPH insulin prebedtime plus regular ...

      Known for Nph Insulin | Type 1 Diabetes | Nocturnal Hypoglycemia | Regular Human | Blood Glucose
      KOL-Index: 16234

      OBJECTIVE: To determine the prevalence of polycystic ovaries as identified by ultrasound in a group of young, postmenarcheal women in the normal population, and to investigate how polycystic ovaries are related to the spectrum of clinical and biochemical symptoms associated with the polycystic ovary syndrome (PCOS).

      DESIGN: Cross-sectional observational study.

      SUBJECTS AND METHODS: Volunteers were recruited from two universities and two general practice surgeries in Oxford. 230 women ...

      Known for Polycystic Ovaries | Prevalence Pcos | Biochemical Features | Acne Hirsutism | Young Women
      KOL-Index: 15975

      1. The effects of insulin-like growth factor I (IGF-I) on the rates of glucose transport and utilization and its interaction with insulin were investigated in rat soleus muscle in vitro. IGF-I increased the rates of glucose transport, lactate formation, glycogen synthesis and the flux of glucose to hexose monophosphate, but it had no effect on the rate of glucose oxidation or glycogenolysis. 2. In the absence of insulin, low levels of IGF-I (0-30 ng/ml) increased the rate of glycolysis ...

      Known for Glucose Transport | Growth Factor | Skeletal Muscle | Igfi Insulin | Lactate Formation
      KOL-Index: 15969

      OBJECTIVE: Untreated GH-deficient adults are predisposed to insulin resistance and excess cardiovascular mortality. We showed previously that short-term treatment with a very low GH dose (LGH) enhanced insulin sensitivity in young healthy adults. The present study was therefore designed to explore the hypothesis that LGH, in contrast to the standard GH dose titrated to normalize serum IGF-I levels (SGH), may have differing effects on insulin sensitivity, body composition, and ...

      Known for Insulin Sensitivity | Cardiovascular Risk Markers | Body Composition | Gh Deficiency | Growth Hormone
      KOL-Index: 15367

      BACKGROUND: Hypoglycemia and hyperglycemia during closed-loop insulin delivery based on subcutaneous (SC) glucose sensing may arise due to (1) overdosing and underdosing of insulin by control algorithm and (2) difference between plasma glucose (PG) and sensor glucose, which may be transient (kinetics origin and sensor artifacts) or persistent (calibration error [CE]). Using in silico testing, we assessed hypoglycemia and hyperglycemia incidence during over-night closed loop. ...

      Known for Loop Insulin | Simulation Studies | Model Predictive Control | Overnight Closed | Statistical Pancreas
      KOL-Index: 15230

      BACKGROUND: Rapid early postnatal weight gain predicts increased subsequent obesity and related disease risks. However, the exact timing of adverse rapid postnatal weight gain is unclear.

      OBJECTIVE: The objective was to examine the associations between rapid weight gain in infancy and in early childhood in relation to body composition at age 17 y.

      DESIGN: This prospective cohort study was conducted in 248 (103 males) singletons and their mothers. Height and weight were measured at birth, ...

      Known for Early Childhood | Fat Mass | Weight Gain Infancy | Body Height | Gestational Age
      KOL-Index: 15041

      OBJECTIVE: Polycystic ovaries are a common ultrasound finding, yet few of these women have many clinical features of polycystic ovary syndrome. Clinical presentation may relate to degree of insulin resistance, common polymorphism at the insulin gene VNTR, and birth weight. We therefore examined the relationship between insulin sensitivity, insulin gene VNTR genotype, birth weight and presence of polycystic ovaries/features of polycystic ovary syndrome in a normal population study.

      DESIGN ...

      Known for Polycystic Ovaries | Birth Weight | Insulin Gene | Ovary Syndrome | Women Clinical
      KOL-Index: 14921

      OBJECTIVE: To identify predictors of postnatal catch-up growth from birth to two years and its relation to size and obesity at five years.

      DESIGN: Regional prospective cohort study.

      SETTING: Avon longitudinal study of pregnancy and childhood, United Kingdom.

      SUBJECTS: 848 full term singletons from a 10% random sample of the Avon longitudinal study of pregnancy and childhood.

      MAIN OUTCOME MEASURES: Maternal birth weight, prepregnancy weight, pregnancy weight gain, height, smoking, and ...

      Known for Years Children | Prospective Cohort | Postnatal Catch | Growth Birth | Pregnancy Childhood

      Key People For Type 1 Diabetes

      Top KOLs in the world
      #1
      John M Lachin
      type 1 diabetes cardiovascular disease complications trial
      #2
      David Matthew Nathan
      type 2 diabetes insulin resistance cardiovascular disease
      #3
      William V Tamborlane
      type 1 diabetes young children growth hormone
      #4
      Patricia A Cleary
      type 1 diabetes optic neuritis intensive therapy
      #5
      George S Eisenbarth
      type 1 diabetes nod mice celiac disease
      #6
      Marian J Rewers
      type 1 diabetes islet autoimmunity celiac disease

      Institute of Metabolic Science, University of Cambridge, Cambridge, UK | Department of Paediatrics, Addenbrooke's Hospital, University of Cambridge, Cambridge, U.K. | Department of Paediatrics, University of Cambridge, Cambridge, UK | Wellcome Trust-

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.